- MoneyShow's Top Pros' Top Picks
- Posts
- Top Pros' Top Picks 1/13/26
Top Pros' Top Picks 1/13/26

Mike Larson | Editor-in-Chief
Stocks are mixed after an intraday bounce on Monday. Crude oil is rising, gold and silver are waffling, and Treasuries are mostly flat.
Let’s call the inflation numbers tame…ish. The Consumer Price Index rose 0.3% on the headline and 0.2% on the core in December. Economists expected both numbers to come in at +0.3%. On a year-over-year basis, consumer prices are up 2.7% overall and 2.6% if you exclude food and energy. The data keeps 2026 Federal Reserve interest rate cuts on the table, though maybe not until later in Q1 or Q2.
Headline, Core CPI (YOY % Change)

Source: Bureau of Labor Statistics
Speaking of the Fed, blowback from the White House-Fed fracas increased yesterday. Global central banks weighed in publicly to support Chair Jay Powell and Treasury Secretary Scott Bessent reportedly warned of economic and political ramifications from the charges. Still, stocks bounced back yesterday and gold cooled off today. That suggests investors are anticipating some kind of resolution or offramp to develop.
Elsewhere in Corporate America, the Q4 earnings season is starting to ramp up. Mega-bank JPMorgan Chase & Co. (JPM) reported earnings excluding certain costs of $14.7 billion, or $5.23 per share. That slightly beat forecasts. On the plus side, trading revenue blew away estimates at $8.24 billion. On the minus side, investment banking fee income missed targets and the bank confirmed that spending in 2025 would remain elevated. JPMorgan stock is up 38.1% in the past year.
Delta Air Lines Inc. (DAL), for its part, was another big name reporting Q4 results. Adjusted earnings per share came in at $1.55 per share, slightly beating the $1.53 forecast. Revenue missed targets, though, and Delta stock dipped despite commentary from CEO Ed Bastian about a “strong start” to 2026. Heading into the report, Delta stock was up 7.3%.
S&P 500 6,977.27 (+0.16%) ↑ | VIX 14.92 (-1.32%) ↓ |
Dow Jones Industrial Average 49,590.20 (+0.17%) ↑ | Gold $4,630.20 per ounce (+0.34%) ↑ |
Nasdaq Composite 23,733.90 (+0.26%) ↑ | Oil $60.38 per barrel (+1.48%) ↑ |
In this episode of the MoneyShow MoneyMasters Podcast, Kenny Polcari and Erin Gibbs of SlateStone Wealth break down how they are approaching the market as leadership broadens and fundamentals start to matter more.
They also explain how after years of narrow performance driven by mega-cap tech, small and mid-cap stocks are beginning to reassert themselves – and highlight where investors can find opportunity without taking unnecessary risk. Plus, they dive deeper into the stocks they highlighted for the just-released MoneyShow 2026 Top Picks Report.
3 Reasons Why You Can’t Miss the 2026 MoneyShow Las Vegas
First is the all-star lineup. Where else can you get critical oil, gas, and renewables insights (and recommendations) from experts like Anas Alhajji of Energy Outlook Advisors? Or future-forward insights and tech trend analysis during an era of massive upheaval from Jason Schenker of Prestige Economics?
Second is the record MoneyMasters Course slate. We have a record-high TEN deep-dive classes waiting for you on-site.
Third is the center-of-it-all venue – and the FUN we have planned. The Paris resort is right in the center of the Las Vegas Strip...and all the dining, entertainment, gaming, and nightlife you could ask for.
Get more details — an secure YOUR event pass — here…
Top Picks 2026: USA Compression Partners LP (USAC)
👉️ TICKERS: ET, USAC
At $24.60 recently, USA Compression Partners LP (USAC) had an indicated annualized yield of 8.5%. We consider USAC a Buy up to $30. This Master Limited Partnership (MLP) is suitable for medium- to high-risk taxable portfolios, suggests Martin Fridson, editor of Forbes/Fridson Income Securities Investor.
Top Picks 2026: Pfizer Inc. (PFE)
👉️ TICKER: PFE
As we head into 2026, healthcare stands out as one of the most dislocated areas of the market. One of our favorite ideas within the sector is Pfizer Inc. (PFE), an iconic American blue chip that has climbed its own crowded wall of worry on top of the broader healthcare exodus, advises Tom Hayes, editor of HedgeFundTips.
💲📈 Don’t Miss the Profits in This 1 Under-the-Radar Stock. (Barchart)




